ArticleHistopathology2026
Glomerular plasmalemma vesicle-associated protein-1 as an endothelial remodelling marker complementing C4d in chronic active antibody-mediated rejection.
Article in Histopathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
aimsChronic active antibody-mediated rejection (caABMR) is a major cause of late kidney allograft failure, yet reliable histological indicators of microvascular injury and therapeutic response remain insufficient. Complement C4d deposition reflects complement activation but does not fully capture endothelial remodelling, particularly in ABO-incompatible transplantation. Plasmalemma vesicle-associated protein-1 (PV-1), encoded by PLVAP and normally absent from glomerular endothelium, is upregulated during endothelial remodelling. We investigated whether glomerular PV-1 complements C4d in identifying active endothelial injury in caABMR. METHODS AND
resultsA total of 429 allograft biopsies from 126 patients with caABMR and 345 surveillance biopsies from 94 stable recipients were analysed. Glomerular PV-1 and C4d immunofluorescence intensities were quantified and correlated with histopathological lesions, renal function, and donor-specific antibodies, with stratification by ABO compatibility. Both PV-1 and C4d were associated with microvascular inflammation and transplant glomerulopathy. While C4d reflected cumulative complement activation and showed staining in ABO-incompatible grafts, PV-1 specifically identified endothelial remodelling, particularly in lesions with double-contour formation, and demonstrated dynamic reduction following B-cell-directed therapy. Low-vacuum scanning electron microscopy correlated with the presence of de novo PV-1 expression in glomerular endothelial cells. In multivariable Cox models incorporating ΔPV-1 and ΔC4d with clinical covariates, ΔPV-1 remained independently associated with death-censored graft survival, whereas ΔC4d did not.
conclusionsGlomerular PV-1 functions as a dynamic marker of endothelial remodelling that complements the static C4d footprint of complement activation. Combined assessment of PV-1 and C4d captures distinct dimensions of microvascular pathology and may refine histopathological evaluation of injury and treatment response in caABMR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.